Details for Patent: 10,117,867

Which drugs does patent 10,117,867 protect, and when does it expire?

Patent 10,117,867 protects CAPLYTA and is included in one NDA.

This patent has twenty-two patent family members in nine countries.

Summary for Patent: 10,117,867

Title:	Methods and compositions for sleep disorders and other disorders
Abstract:	Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
Inventor(s):	Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
Assignee:	Intra Cellular Therapies Inc
Application Number:	US15/467,867
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,117,867
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 10,117,867

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No	10,117,867					TREATMENT OF BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	10,117,867					TREATMENT OF BIPOLAR DEPRESSION
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	10,117,867					TREATMENT OF BIPOLAR DEPRESSION

International Family Members for US Patent 10,117,867

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009251816
Australia	2015218433
Canada	2725342
China	102105059
China	105168219